Marcelo Matiello, MD
Neurology · New Haven, CTNPI 1598027898
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,715 of the $39,821 with a category attached, or 82.2%. 8 manufacturers reported payments, led by Genentech USA, Inc. at 34.3% of the total. Reporting peaked in 2022 at $10,703 and has fallen 64.3% since, to $3,823 in 2025.
Across 51 payments — averaging $780.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$14K
- AstraZeneca$12K
- Amgen$7K
- F. Hoffmann-la Roche AG$4K
- Ipsen Biopharmaceuticals, Inc$3K
- TG Therapeutics, Inc.$262
- plus $210 from 2 others
What the payments were for
- Consulting fees$32,71582%
- Speaking & faculty fees$3,0008%
- Travel & lodging$1,4144%
- Food & beverage$2,6737%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 14 | $13,664 |
| AstraZeneca | 9 | $12,151 |
| Amgen(2 entities) | 15 | $6,944 |
| F. Hoffmann-la Roche AG | 2 | $3,549 |
| Ipsen Biopharmaceuticals, Inc | 6 | $3,041 |
| TG Therapeutics, Inc. | 3 | $262 |
| Genentech, Inc. | 1 | $190 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,821 in reported general payments places this provider in the 85th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 38 | $203,760 |
| CopaxoneGlatiramer Acetate | 24 | $137,678 |
| Kesimpta PenOfatumumab | 13 | $127,635 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,452 |
| Dalfampridine ErDalfampridine | 25 | $7,240 |
| Mycophenolate Mofetil | 12 | $3,639 |
| Carbamazepine ErCarbamazepine | 16 | $2,364 |
| Modafinil | 18 | $1,507 |
| Gabapentin | 81 | $959 |
| Pregabalin | 60 | $704 |
| Topiramate | 34 | $593 |
| Memantine Hcl ErMemantine Hcl | 13 | $343 |
| Tizanidine Hcl | 28 | $342 |
| Primidone | 13 | $320 |
| Sumatriptan Succinate | 14 | $240 |
Paid to pharmacies, not to this prescriber.
Other neurology in New Haven
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Stephen WaxmanNew Haven$252K
- Ariel LeflandNew Haven$220K
- David RussellNew Haven$208K
- Richard NowakNew Haven$126K
- David HaflerNew Haven$118K
- Kenneth MarekNew Haven$86K
- Daniel DicapuaNew Haven$85K
- Lee SchwammNew Haven$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.